Clinical research and clinical trials are vital in the development and evaluation of new diagnostics, vaccines, and therapeutics for infectious disease. Once one of these interventions has been tested in clinical trials and is proven safe and effective in humans, it may be considered for licensure.
DMID is responsible for supporting extramural clinical research to control and prevent diseases caused by a variety of human infectious agents. Spanning the pipeline from clinical science and product development to research studying optimal utilization strategies, DMID has a number of programs dedicated to advancing clinical research.
DMID supports clinical research nationally and internationally on numerous pathogens, including those causing severe diarrhea, skin infections, and respiratory illnesses. The clinical research program addresses tuberculosis, malaria, antimicrobial resistance, tropical infectious diseases, sexually transmitted diseases, enteric pathogens, bacterial and viral respiratory pathogens, influenza research and surveillance, and biodefense product development.
For more information on the DMID clinical research program, please see
Last Updated May 13, 2015